Tranquis Therapeutics to Present Preclinical Data on TQS-168 at ARDD 2022
29 Aug 2022 //
BUSINESSWIRE
Tranquis Therapeutics Granted FDA ODD for TQS-168 in ALS
21 Jun 2022 //
BUSINESSWIRE
Tranquis Therapeutics concludes Phase I ALS treatment trial
03 Jun 2022 //
CLINICALTRIALSARENA
Tranquis Therapeutics Announces Successful Completion of PI Trial of TQS-168
02 Jun 2022 //
BUSINESSWIRE
Tranquis Therapeutics Announces Participation in March Investor Conferences
22 Mar 2022 //
BUSINESSWIRE
Tranquis Therapeutics Presents Positive Preclinical Data on TQS-168
03 Nov 2021 //
BUSINESSWIRE